 | | Vol. 11.46 – 26 November, 2020 |
| |
|
|
| Smurf2 induced the ubiquitination of Smad1/5. Bone morphogenetic protein (BMP)/Smad signaling was enhanced in Smurf2−/− bone marrow stromal cells (BMSCs) stimulated with recombinant human BMP2, and the inhibition of BMP/Smad signaling suppressed osteogenic differentiation of these BMSCs.
[Bone Research] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| A bioinspired staged bone regeneration strategy which loads bone morphogenetic protein2 (BMP2)‐modified black phosphorus nanosheets to a polylactic acid electrospun fibrous scaffold, with a combination of recruiting osteoblast precursor cells and biomineralization properties for bone regeneration, was constructed successfully by micro‐sol electrospinning technique.
[Small] |
|
|
|
| ECM subtypes, defined by relative levels of laminin and vitronectin expression in patient tissue microarrays and gene expression data sets, were able to identify novel high‐risk medulloblastoma patient subgroups and predict overall survival.
[Journal of Pathology] |
|
|
|
| Scientists showed that in pancreatic tumors, the developing stroma increased tumor initiation frequency in pancreatic cancer cells in vivo by enriching for CD133+ aggressive “stem-like” cells.
[Cell Death & Disease] |
|
|
|
| Investigators explored the predictive role of legumain—which showed the ability in ECM degradation—in an acute myocardial infarction patient cohort and investigated the underlying mechanisms.
[Cell Death & Disease] |
|
|
|
| Researchers introduced a microfluidic model of the solid tumor-vascular interface composed of a human umbilical vein endothelial cell-lined, perfusable, bioengineered blood vessel and tumor spheroids embedded in an ECM.
[Scientific Reports] |
|
|
|
| The authors report a technique to reconstruct cardiovascular tissue using multiscale scaffolds incorporating polycaprolactone fibers with double-layered hydrogels comprising fibrin hydrogel surrounded by secondary alginate hydrogel.
[Scientific Reports] |
|
|
|
| Scientists indicated that upregulation of miR-211 has tumor-suppressive properties by inhibiting TGF-β pathway activation via inhibin-β A (INHBA) in prostate cancer stem cells.
[Cancer Gene Therapy] |
|
|
|
| Investigators used a tumor organoid model, consisting of hepatic stellate cells embedded in Collagen-1 and colorectal cancer cell spheroids, to determine the relationship between ECM architecture, cancer cell malignancy, and chemoresistance.
[iScience] |
|
|
|
| The authors report a biodegradable scaffold material composed of recombinant polypeptide based on the human type I collagen alpha 1 chain as a source of hydrogel-based graft materials.
[Communications Materials] |
|
|
|
|
| Scientists discuss the transformative experimental strategies that are being leveraged to dissect the key cellular and molecular mechanisms that regulate fibrosis, and the translational approaches that are enabling the emergence of precision medicine-based therapies for patients with fibrosis.
[Nature] |
|
|
|
| Cancer cells do not exist in isolation: rather, they exist within a complex microenvironment composed of stromal cells and ECM. Within this tumor microenvironment exists an interplay between the two main stromal cell subtypes, cancer-associated fibroblasts and immune cells, that are important in controlling metastasis.
[British Journal of Cancer] |
|
|
|
| Recent developments in inorganic nanocomposite hydrogels for bone tissue engineering that are of vital importance but have not yet been comprehensively reviewed are summarized.
[iScience] |
|
|
|
|
| Epic Sciences, Inc. has entered into an exclusive license and collaboration agreement with Dr. Peter Kuhn and the USC Michelson Center for Convergent Bioscience. The collaboration will improve Epic’s platform and enable more precise characterization of rare circulating tumor cells and cells from the tumor microenvironment, which Epic is developing into liquid-biopsy diagnostics used for characterizing a patient’s cancer to guide treatment decisions.
[Epic Sciences, Inc.] |
|
|
|
| Aziyo Biologics, Inc. has been awarded a group purchasing agreement with Premier Inc., for Premier’s Technology Breakthroughs Program. The new agreement allows Premier members to take advantage of special terms for Aziyo’s CanGaroo® Envelope – a 510(k) FDA-cleared and CE-Marked ECM envelope intended to securely hold a cardiac implantable electronic device or an implantable neurostimulator to create a stable environment when implanted in the body.
[Aziyo Biologics, Inc.] |
|
|
|
| Catamaran Bio, Inc. has launched with $42 million in financing. Proceeds will be used to advance the company’s two lead chimeric antigen receptor (CAR)-NK cell therapy programs. In addition, funding will expand the company’s TAILWIND™ Platform, an integrated and proprietary suite of technologies for designing, genetically engineering, and manufacturing allogeneic CAR-NK cell therapies to neutralize the hostile tumor microenvironment.
[Catamaran Bio, Inc.] |
|
|
|
|
| March 1 – March 4, 2021
Virtual |
|
|
|
|
|
| | University of Illinois at Chicago College of Medicine – Chicago, Illinois, United States |
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| | Edward Via College of Osteopathic Medicine – Blacksburg, Virginia, United States |
|
|
|
| | H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States |
|
|
|
| | Medical University of Vienna – Vienna, Austria |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
